NeuroSurvival Technologies gets financing, changes name
Article Thumbnail ImageAugust 20, 2008 -- Molecular imaging and therapy developer NeuroSurvival Technologies (NST) of Petach-Tikva, Israel, has completed $13.3 million in financing and changed its name.
Member Sign In:
  MemberID or E-mail Address:
  Password:
(?)

New AuntMinnie.com Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • Online CME
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • NST now will be known as Aposense, the same name as the company's molecular imaging agent for programmed cell death.

    The Aposense agent, currently under development, is designed to detect signs of apoptosis, a genetically controlled process of cell death that is associated with most medical disorders. Potential clinical applications include oncology, neurology, and cardiology.

    Related Reading

    IBA, NeuroSurvival Technologies partner, August 14, 2008

    NST is cleared for Aposense trials, July 25, 2008

    Copyright © 2008 AuntMinnie.com


    || About || Advertising || AuntMinnieCME.com || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2014 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2014 AuntMinnie.com. All Rights Reserved.